Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124293 · ClinicalTrials.gov registry record
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
A clinical trial of Trauma and Acquired Bleeding Disorder, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 63
- Enrollment target
- 2
- Study locations
NCT00124293: Completed study of Trauma and Acquired Bleeding Disorder, sponsored by Novo Nordisk A/S.
NCT00124293 is a study of Trauma and Acquired Bleeding Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 63 participants, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00124293, a study of Trauma and Acquired Bleeding Disorder, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.
Conditions Studied
Interventions
- DRUG activated recombinant human factor VII
Study Locations (2)
New Jersey
- Novo Nordisk Investigational Site - Plainsboro
Other
- Novo Nordisk Investigational Site - Mississauga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2004-10-06 |
| Est. Completion | 2005-11-23 |
What the finished NCT00124293 record still lists
NCT00124293 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Trauma appearing as the primary indexed condition, and to 1 intervention - of which activated recombinant human factor VII is the first listed.
NCT00124293 reports a single indexed study location in New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00124293 about?
NCT00124293 is a clinical study titled "Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury". This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.
What is the current status of trial NCT00124293?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2004-10-06. Estimated completion is 2005-11-23.
What conditions does trial NCT00124293 study?
This clinical trial studies the following conditions: Trauma, Acquired Bleeding Disorder.
What interventions are being tested in trial NCT00124293?
The interventions under investigation include: activated recombinant human factor VII (DRUG).
Who is sponsoring clinical trial NCT00124293?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00124293 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trauma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00124293's enrollment target sits among peer trials
63 37th of 56 higher than 20 of 56 other Trauma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Trauma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RECRUITING · Phase 2
-
Testing FIRST in Youth Outpatient Psychotherapy
RECRUITING · NA
-
PRESERVE & CONNECT: Impact Study of the BPC
RECRUITING · NA
-
Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)
RECRUITING · NA
-
PMCF Study to Evaluate the VERTICALE® Cervical System in Spine Surgery According to Its Intended Use.
RECRUITING
-
Evaluation of the Parenting in the Moment Online Program for Forcibly Displaced Families
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI